 |
|
Apparent Warfarin Potency Inconsistencies Compromise Effectiveness
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
An alternative message can perhaps be derived from the article by Meyer et al.1 The article documents that INR was outside therapeutic range in 59% of patients receiving warfarin. The inference is that appropriate levels of anticoagulation control were not achieved in almost half. Is this acceptable? Is there a problem with the paradigm or is medication potency undependable?
Such a problem was uncovered several years ago when inconsistency in warfarin sodium (Coumadin; DuPont Pharma, Wilmington, Del) potency was discovered.2 At that time, the problem was attributed to excess heat exposure during postal transport of the mail order prescription. Subsequently, we have had reason to suspect a larger problem. Wide weekly variation in individual patient dosage response made anticoagulation control challenging.3 A search for confounding factors was unsuccessful. Only the Dupont trade name product had been provided. There had been no alteration in concomitant medication or health product ingestion or . . . [Full Text of this Article]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Comparison of Low-Molecular-Weight Heparin and Warfarin for the Secondary Prevention of Venous Thromboembolism in Patients With Cancer: A Randomized Controlled Study
Guy Meyer, Zora Marjanovic, Judith Valcke, Bernard Lorcerie, Yves Gruel, Philippe Solal-Celigny, Christine Le Maignan, Jean Marc Extra, Paul Cottu, and Dominique Farge
Arch Intern Med. 2002;162(15):1729-1735.
ABSTRACT
| FULL TEXT
|
